At Adalid, we are dedicated to advancing pharmaceutical solutions through the development of novel lipid nanoparticle technology. By leveraging LNPs, we aim to enhance the stability and bioavailability of drugs, improving their therapeutic efficacy while minimizing potential side effects.
Adalid Sciences
Based in the heart of Europe, in Prague, Czech Republic, Adalid was established in June 2024 as a spin-off from the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences. Our foundation is built on a legacy of scientific excellence and innovation.
With the financial backing of a robust and committed partner, we are well-equipped to pursue long-term cooperation and bring our groundbreaking technology to partners and clients worldwide. This strategic support enables us to accelerate our research and development efforts, fostering collaborations that push the boundaries of genomic medicine and beyond.
Our team has accumulated decades of expertise in using lipid nanoparticles as a delivery system for nucleic acids and related fields. With our strong background in synthetic chemistry, biochemistry, and nanoparticle formulation, we can provide added value and seamlessly integrate into our clients' workflows.
Our Team
Klara Grantz Saskova
Co-Founder and Chief Executive Officer
Klara has successfully led the LNP project at IOCB Prague for three years, guiding it from academia to a standalone spin-off company. In addition to her work on LNPs, she is an expert in biochemistry and leads a research group at Charles University focusing on medicinal chemistry and virology. Her distinguished career is connected to both the IOCB and her alma mater, the Faculty of Science at Charles University.
Petr Cigler
Co-Founder and Chief Scientific Officer
Petr is a distinguished Czech scientist who turned his innate childhood curiosity into a successful career, culminating in a PhD in chemistry. After two years at the Scripps Research Institute (CA), he returned to Prague where he leads a research group at IOCB. In his spare time, Petr pursues his passion for music by playing the French horn and has received critical acclaim as a composer of modern instrumental music and operas.
Frantisek Sedlak
Co-Founder and Chief Medical Officer
As a trained physician, Frantisek continues to see his patients at a leading medical institution. In Adalid he will focus on the regulatory approval of our products and oversees the medical implications of the application of our technology. As an active scientistific researcher, Frantise also supervises the operations revolving around the formulation of our LNPs.
David Schreib
Co-Founder and Chief Commercial Officer
David has broad experience in both legal and business affairs in private as well as public sector. David manages the commercial, legal and operational aspects of Adalid Sciences, ensuring that our scientific teams have the best possible conditions to excel in their work and that our clients feel confident in their partnership with Adalid Sciences.
Team of Experienced Professionals
We have an expert team of scientists ready to advance our clients' projects and continue developing our technology. With 5 nationalities and over 70 % share of Ph.D. holders, our diversified staff brings top class expertise in the areas related to LNPs, including synthetic chemistry, biochemistry and formulations. Working in newly equipped laboratories, we are looking forward to tackle all challenges brought to us by our partners.